Canadian type 1 diabetes research to receive JDRF cash injection

The Canadian government and JDRF have announced a new $30m (£24m) partnership to develop new and better treatments for people with diabetes.
Through the Canadian Institutes of Health Research (CIHR), the partnership will support clinical trials researching type 1 diabetes and accelerate efforts to find a cure for the condition. Both CIHR and JDRF have committed $15m to the partnership, for a total investment of $30M.
“This new partnership will focus the efforts of the diabetes research community in Canada and speed the development of new and better treatments for type 1 diabetes,” said Dr Phillip Sherma, Scientific Director of the CIHR Institute of Nutrition, Metabolism and Diabetes.
Derek Rapp, CEO of JDRF International, added that the charity is pleased to be entering this exciting partnership given Canada’s “state-of-the-art type 1 diabetes research.”
The health of people in Canada with type 1 diabetes is also high on the agenda, and the funding will help improve health outcomes and quality of care for more than 300,000 Canadians living with type 1 diabetes.
The Honourable Jane Philpott, Minister of Health, said: “The Government of Canada recognises the impact that type 1 diabetes has on Canadians and their families.
“This research will help improve the quality of life for Canadians living with type 1 diabetes and drive efforts to find a cure for this condition.”
Dave Prowte, President and CEO at JDRF Canada, added: “We are honoured to partner with CIHR to continue funding the best and brightest scientists in the field.
“This partnership will enable JDRF Canada to make significant advancements in the fight against diabetes and to positively impact the lives of the hundreds of thousands of Canadians currently living with type 1 diabetes.”

To Top